Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +/- X (where X is any additional drug). Adverse events and change in disease activity will be assessed. Venetoclax is an approved drug for the treatment of CLL. Study doctors put the participants in 1 of 2 groups, called cohorts, based on when symptoms of CLL came back after previous trea

Trial Details

NCT ID
NCT04895436
Phase
PHASE2
Sponsor
AbbVie
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax
  • Obinutuzumab
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Des Moines, Iowa, United States|41.60054,-93.60911
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

  • Documented diagnosis of chronic lymphocytic leukemia (CLL) that requires treatment for CLL according to International Workshop for Chronic Lymphocy…
  • Previously completed venetoclax + anti-CD20 antibody +/- X regimen as a fixed duration first-line (1L) therapy and achieved documented response, de…
  • More than 24 months (Cohort 1) or 12-24 months (Cohort 2) have elapsed between last dose of venetoclax and disease progression after completion of …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →